BDBM618975 US20230295110, Compound 9.

SMILES Cc1c(O)c(ncc1-c1ccc(nc1)C(F)(F)F)C(=O)NCC(O)=O

InChI Key InChIKey=COQYEYFGBWPFGZ-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 618975   

TargetProlyl hydroxylase EGLN2(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618975(US20230295110, Compound 9.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetProlyl hydroxylase EGLN3(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618975(US20230295110, Compound 9.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent

TargetEgl nine homolog 1(Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM618975(US20230295110, Compound 9.)
Affinity DataIC50: 100nMAssay Description:Time-resolved fluorescence resonance energy transfer (TR-FRET) assay was utilized to determine the enzymatic half maximal inhibitory concentration (I...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2023
Entry Details
US Patent